Mechanism of bigelovin in treatment of imiquimod-induced psoriasiform mouse model
- Author:
Yue ZHANG
1
;
Zheng-Xin XU
1
;
Yi LU
2
;
Jing-Wen YANG
2
;
Yu-Kai WANG
2
;
Meng-Ying ZHANG
2
;
Fang ZHOU
2
;
Guang-Ji WANG
2
;
Zheng-Xin XU
3
Author Information
- Publication Type:Journal Article
- Keywords: bigelovin; imiquimod; inflammation; psoriasis; Th17 cells; Treg cells
- From: Chinese Pharmacological Bulletin 2022;38(12):1801-1808
- CountryChina
- Language:Chinese
- Abstract: Aim To investigate the effects of bigelovin on mouse model of imiquimod-induced psoriatic itch and its mechanism. Methods Psoriasis-like mouse model was established by applying imiquimod cream on the back skin of mouse. Psoriasis area and severity index, pathological changes, the expression levels of inflammatory factors and related molecular biological data were used as effect indicators. The changes of the above parameters were observed after administration of different concentrations of bigelovin. Then the possible mechanism of the effects was further analysed.Results Compared with the model group, bigelovin significantly decreased the symptoms of skin lesions and reduced the PASI score. Bigelovin alleviated epidermal thickening and reduced the expression of Ki67 in a dose-dependent manner. The expression levels of inflammatory factors were reduced in both skin and serum.The percentage of Th17 cells was reduced and the percentage of Treg cells was increased in the lymph node.In addition, bigelovin also inhibited the phosphorylation of P65 protein and significantly reduced the nuclear localization of P65, suggesting that bigelovin might inhibit the activation of P65 protein. Conclusions The effect of bigelovin on improving the signs and symptoms of imiquimod-induced psoriasis mice may be related to the inhibition of P65 protein phosphorylation in keratinocytes.
